Biotech Startups
9,835 companies tagged Biotech, with their investors and founders.
Goryo Chemical develops fluorescence-based technology to visualize diseases and support diagnosis and treatment. The company applies chemistry to medical and healthcare applications for patients and clinicians.
3 investors
Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases. The company operates manufacturing facilities in China and was acquired by AstraZeneca in February 2024.
3 investors
GraphTx is an AI-driven platform for drug discovery that validates immunology and inflammation drug targets using live patient samples before clinical trials. The company serves pharmaceutical researchers by applying machine learning to patient immune cell data to reduce development risk and failure rates.
3 investors
Greenitio develops bio-based specialty ingredients that replace petrochemical and microplastic-based materials in cosmetics and personal care, using a patented green chemistry platform to convert natural polymers into biodegradable alternatives. Its materials target functions such as SPF boosting, texture, and stability, and address the EU's upcoming ban on intentionally added microplastics.
3 investors
3 investors
Grit Bio develops nine core technology platforms for cell therapy manufacturing and development, spanning TIL expansion, viral vector production, immunological target discovery, and LNP delivery systems for therapeutic applications.
3 investors
GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function. Its pipeline is built on two NSAA chemistry families—DuraLogic for therapeutic stability and dosing, and ProGly for biologics addressing autoimmune disease and immunogenicity.
3 investors
Grove AI builds "Grace," an AI agent and participant relationship management (PRM) platform that automates clinical trial recruitment tasks such as prescreening, participant inquiries, and appointment scheduling. It serves clinical research sites, CROs, and pharmaceutical sponsors in the life sciences industry.
3 investors
Hadean Ventures is a European venture capital fund manager with over EUR 230 million in assets under management, with a track record in life sciences. The firm invests across sectors and stages, focusing on science-driven innovation and healthcare.
3 investors
HarborSite develops a targeted gene insertion platform that engineers site-specific recombinase enzymes to integrate therapeutic genes into safe genomic sites. It aims to create one-time, durable treatments for genetic and age-associated diseases.
3 investors
Harmonic Discovery applies medicinal chemistry, cheminformatics, data science and machine learning expertise to advance drug discovery. The company is supported by investors at the intersection of technology, biology and medicine.
3 investors
Hera Biotech develops diagnostics for women's health, aiming to detect conditions that legacy tools miss. Its platform is presented as AI-enabled and science-based, intended for clinical care settings.
3 investors
Hera Health Solutions is a biotechnology company that develops a proprietary nanotechnology platform to reformulate existing pharmaceutical compounds into more effective and longer-acting therapies. The platform enables rapid optimization of drugs with improved release profiles, reduced toxicity, and scalable manufacturing.
3 investors
HiberCell develops therapeutic candidates targeting the Integrated Stress Response pathway to address treatment-resistant cancers, relapse, and metastasis. The company focuses on cancer patients who have experienced treatment resistance through novel drug development approaches.
3 investors
HiFiBiO Therapeutics develops immunotherapies for patients with high unmet medical needs, using its Drug Intelligence Science (DIS) platform that combines single cell technology with AI/ML analytics. The platform supports target discovery, antibody selection, and predictive biomarker identification for drug development.
3 investors
Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones. It applies disease-specific genetic markers to identify patient populations most likely to benefit from its targeted treatments.
3 investors
HistoWiz provides digital pathology services including precision histology, immunostaining, slide archiving, and AI-powered image analysis for research and clinical laboratories. The company serves biomedical researchers, pharmaceutical companies, and diagnostic labs with automated histology processing and pathology consultation.
3 investors
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
3 investors
Humacyte is a regenerative medicine company that develops a bioengineered, human-derived Acellular Tissue Engineered Vessel (ATEV) along with a scalable cell sourcing and manufacturing platform. Its off-the-shelf vessels target vascular trauma, AV access, and peripheral artery disease (PAD), and have received FDA Regenerative Medicine Advanced Therapy designation.
3 investors
Huue produces bio-based indigo dye for the denim industry using bioengineered microbes that convert sugar into pigment, replacing toxic chemical and petroleum-based processes. The company's sustainable indigo is compatible with existing manufacturing and reduces toxicity, fossil fuel use, and water pollution in denim production.
3 investors
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins. The company operates in drug discovery, using its proprietary Hyku platform to address challenges such as selectivity, druggability, and resistance in disease targets.
3 investors
IDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.
3 investors
Identical Implant develops dental implant technology. The company's specific products and target market are not described on this page excerpt.
3 investors
IDRx discovers, develops and delivers medicines and vaccines focused on cancer, HIV, respiratory diseases, and infectious diseases. The company aims to positively impact the health of 2.5 billion people by the end of the decade.
3 investors